Advocacy intelligence hub — real-time data for patient organizations
Cerus Corporation
Erasmus Medical Center
RiaSTAP: FDA approved
Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
RiaSTAP
CSL Behring, LLC
RiaSTAP
(human fibrinogen concentrate, pasteurized)Orphan drugCSL Behring, LLC
Program Director, Clinical R&D
CSL Behring
Cristina Solomon, MD
Octapharma
Program Director
CSL Behring
Claudia Djambas Khayat, MD
Hôtel Dieu de France, Dept. of Pediatrics
Sigurd Knaub, PhD
Octapharma
Alessandro Casini, MD
University Hospitals of Geneva